SEC Form 4 · accession 0001790340-26-000082
Immuneering Corp · IMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Gengos
Officer — Chief Financial Officer
Period of report
Jul 16, 2026
Accepted (ET)
Jul 17, 2026 · 4:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001790340
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $4.78 | Jul 16, 2026 | A | 650,000 | A | — | Jul 16, 2036 | Class A Common Stock | 650,000 | 650,000 | D |
Explanation of responses
- F1Subject to the reporting person's continued employment through each applicable vesting date, 8.33333% of the shares underlying the stock option shall vest on each of the first, second and third monthly anniversary of the grant transaction date (the "Grant Date"); 1.6667% of the shares underlying the stock option shall vest on the fourth monthly anniversary of the Grant Date and on each monthly anniversary thereafter until the one year anniversary of the Grant Date; 3.33333% of the shares underlying the stock option shall vest on each monthly anniversary following the one-year anniversary of the Grant Date until the second anniversary of the Grant Date; and 0.833333% of the of the shares underlying the stock option shall vest on each monthly anniversary following the second anniversary of the Grant Date until the fourth anniversary of the Grant Date, such that all shares underlying the stock option shall be fully vested on the fourth anniversary of the Grant Date.